AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00278837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based meditation program
Description: Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
Study NCT01638351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Progressive resistance exercise training, 3 times a week for 12 weeks.
Study NCT01638351 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants in this arm will receive a brochure specific for type 2 diabetes mellitus about the general principles of exercise, nutrition, and diet. They are asked to maintain their activity level.
Study NCT00609375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefepime
Description: Administration of cefepime in continuous infusion (3 Gr over 24 hours) for 7-14 days at the discretion of the investigator. Administration of saline solution 0.9%, 50-100 mL over 30 minutes every 8 hours.
Study NCT00609375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefepime
Description: Administration of cefepime in intermittent infusion (1 Gr over 30 minutes every 8 hours) for 7-14 days at the discretion of the investigator.Administration of saline solution 0.9%, 50-250 mL over 24 hours
Study NCT02484053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Giving rituximab as a rapid infusion over a period of 90 or 120 minutes.
Study NCT03174587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogenic bone marrow derived mesenchymal stem cells
Description: Step -1 dose : 1.0x10\^6cells/kg Step 1 dose : 2.0x10\^6cells/kg Step 2 dose : 3.0x10\^6cells/kg The single injection of CS20AT04 Inj. in the peripheral veins.(IV) The duration of follow up study following the single dose of CS20AT04 is 28 days
Study NCT02650687 — intervention group
Intervention type: PROCEDURE
Intervention: Processed EEG
Description: In the operating room. Processed EEG will be measured using the Bispectral Index (BIS) monitor which is standard of care.
Study NCT00765453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone marrow derived progenitor cells or placebo infusion
Description: Over-the-wire balloon catheter delivers infusion into coronary vessel using a stop-flow technique
Study NCT00765453 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Placebo infusion
Study NCT03782675 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The Air Barrier System will be deployed onto the surgical field, but the airflow will not be activated, so this is a sham control comparator.
Study NCT03782675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Barrier System
Description: The Air Barrier System is a device that uses localized clean air flow to shield a surgery site from ambient airborne microorganisms that are shed into the air from people present in the operating room.
Study NCT04006353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT
Description: 320 mg, Intravenous infusion
Study NCT04006353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIF
Description: 600mg q.d.
Study NCT00357942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution for injection every 3 hour for 24 hours
Study NCT00357942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for injection every 3 hour for 24 hours
Study NCT01737528 — intervention group
Intervention type: PROCEDURE
Intervention: Transcatheter Aortic Valve Replacement
Description: Minimal invasive implantation of a biological prothesis in Aortic Position
Study NCT03348995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bridge-Enhanced ACL Restoration (BEAR)
Description: In the BEAR Procedure, surgery is performed to sew the ACL back together and a scaffold is placed between the torn ends at the time of repair.
Study NCT02908347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP1032
Description: hard gelatine capsules containing 50 mg MP1032 as active ingredient
Study NCT02908347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: hard gelatine capsules without active ingredient
Study NCT00829556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integuseal
Study NCT03631641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04192149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
Study NCT04323059 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standardized milk-based formulation
Description: Nutritional formulations prepared from locally available food stuffs for reversing childhood malnutrition
Study NCT04323059 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized milk-based formulation
Description: Nutritional formulations prepared from locally available food stuffs for reversing childhood malnutrition
Study NCT03539887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Description: Intranasal ketamine will be prepared as 100mg/ml ketamine in 0.9% saline. An mucosal atomization device will be used to provide 5 intranasal applications of solution (volume 100 μl), separated by 3 minutes, over a total of 15 minutes. Each of five ketamine applications will provide 10 mg of study drug, for a total of 50mg. The dose to be used (0.5-1mg/Kg) is 6 to 18 times lower than the sedation dose (6-9mg/Kg).
Study NCT03539887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline alone. An mucosal atomization device will be used to provide 5 intranasal applications of saline (volume 100 μl), separated by 3 minutes, over a total of 15 minutes.
Study NCT00337259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: D1 and 8, Gemcitabine 1250mg/m2 + NS 100ml MIV over 30min, every 3 weeks
Study NCT01949974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Palliative Chemotherapy
Description: Standard Palliative Chemotherapy, depending on type cancer.
Study NCT01949974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integral Attention Program (PAI)
Description: The PAI is a plan of care and treatment adapted in accordance with the evolution and needs of patients. This plan includes an initial comprehensive assessment of patients and their families during the first visit, including specialized psychological and social support when needed, voluntary art therapy and/or mindfulness. There will be outpatient monitoring, 24h phone assistance, home visits, support should hospitalization be required, and unscheduled visits by a palliative care team.
Study NCT01949974 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integral Attention Program (PAI)
Description: The PAI is a plan of care and treatment adapted in accordance with the evolution and needs of patients. This plan includes an initial comprehensive assessment of patients and their families during the first visit, including specialized psychological and social support when needed, voluntary art therapy and/or mindfulness. There will be outpatient monitoring, 24h phone assistance, home visits, support should hospitalization be required, and unscheduled visits by a palliative care team.
Study NCT00002844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Daily intravenous infusions of cyclophosphamide for two days,
Study NCT00002844 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
Study NCT00002844 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Transplantation
Description: After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
Study NCT00002844 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: Following 2 days of cyclophosphamide, TBI in four daily exposures then bone marrow transplant.
Study NCT01077492 — intervention group
Intervention type: OTHER
Intervention: Virtual Bronchoscopy Navigation
Description: Use of dedicated virtual bronchoscopy navigation software using 4D CT-PET scan spacial data.
Study NCT01453868 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non Impact Aerobics
Description: a 12 week, twice a week class in non impact aerobics
Study NCT00058292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Carmustine is given at a dose of 300 mg/m2 intravenous infusion over a 2 hour period on treatment day -6 (Day 0 = stem cell transplant).
Study NCT01453868 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive : lecture series
Description: a 12 week, once a week for one hour lecture series with no exercise. Topics will cover symptom management in Multiple Sclerosis
Study NCT00058292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Cytarabine is given at a dose of 100 mg/m2 intravenous infusion over a 1 hour period, every 12 hours on treatment days -5, -4, -3, and -2, for a total of 8 doses (Day 0 = stem cell transplant).
Study NCT00058292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Etoposide is given at a dose of 100 mg/m2 intravenous infusion over a 2 hour period every 12 hours on treatment days -5, -4, -3, and -2, for a total of 8 doses (Day 0 = stem cell transplant).
Study NCT04037865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: PF-06651600 50 mg oral tablets will be administered on Days 1 to 10
Study NCT03477045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single dose fish oil
Description: Fish oil consumed within a single high fat test meal
Study NCT03477045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Repeated dose fish oil
Description: Fish oil consumed daily for 8 weeks
Study NCT03477045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: single dose Camelina seed oil
Description: camelina seed oil consumed within a single high fat test meal
Study NCT03477045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: repeated dose camelina seed oil
Description: camelina seed oil consumed daily for 8 weeks
Study NCT00058292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Melphalan is given at a dose of 140 mg/m2 as an intravenous infusion over a 1 hour period on treatment day -1 (Day 0 = stem cell transplant).
Study NCT00549315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant Endoluminal Stent-Graft Stent-Graft Balloon Catheter
Description: VALIANT stent-graft endoprosthesis is inserted by the Xcelerant Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
Study NCT02625805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG monitoring (MindWave by NeuroSky)
Description: EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises. Additional EEG monitoring will be performed during performance of a computerized test using MindWave Headset.
Study NCT02625805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG monitoring (EPOC by Emotiv)
Description: EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
Study NCT02625805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate will be administered to each of the study participants in both groups in one of the two days on the study selected randomly.
Study NCT01381393 — intervention group
Intervention type: DRUG
Intervention: Ibandronate
Description: Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Study NCT00035490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azimilide Dihydrochloride
Description: 125 mg azimilide, once a day for one year
Study NCT00035490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet, once daily for one year
Study NCT00035490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azimilide Dihydrochloride
Description: 75 mg azimilide, once a day for one year
Study NCT01679405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: once daily per os
Study NCT00998998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home stimulation
Description: Weekly visit of one hour to the home over the course of one year to foster the mother-child relationship.
Study NCT04190914 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pulp regeneration for necrotic primary teeth
Description: a pulp regeneration procedure will be applied for necrotic primary teeth with different intracanal medication compared to conventional pulpectomy used in treatment for necrotic primary teeth
Study NCT04190914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulp regeneration for necrotic primary teeth
Description: a pulp regeneration procedure will be applied for necrotic primary teeth with different intracanal medication compared to conventional pulpectomy used in treatment for necrotic primary teeth
Study NCT04689516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thoracic fluid content estimation
Description: The patient will be monitored for thoracic fluid content and LUS score. The infusion will stop if TFC reaches 40 k ohm-1 or after completion of the infused volume. LUS evaluation will be done before the start and after the end of the infusion.
Study NCT00597688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gel
Description: Oral mucosal application of chlorhexidine gel
Study NCT00597688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Oral mucosal application of placebo gel
Study NCT00410956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00410956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT00410956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: floxuridine
Study NCT00410956 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Study NCT00410956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Study NCT00410956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Study NCT00410956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00998998 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Surveillance
Description: Weekly visits to the home over the course of one year to record iron intake, feeding, and health information.
Study NCT00998998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron
Description: Six-month-old infants treated orally for 1 y with 15 mg elemental Fe/d as ferrous sulfate. Twelve-month old infants treated orally for a minimum of 6 months with 30 mg elemental Fe/d.
Study NCT00998998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron
Description: Six-month-old infants treated orally for 1 y with 15 mg elemental Fe/d as ferrous sulfate. Twelve-month old infants treated orally for a minimum of 6 months with 30 mg elemental Fe/d.
Study NCT01755208 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: light-scattering spectroscopy
Description: Undergo light-scattering spectroscopy
Study NCT01427595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500-2000 mg PO BID (X12 weeks)
Study NCT00058292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: On day 0, a minimum of 2.0 X 106 CD34+ cells/kg unselected peripheral blood progenitor cells (PBPC) will be reinfused following institutional guidelines for the reinfusion procedure.
Study NCT00058292 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Description: Patients will receive 90Y2B8 at a variable dose on treatment day -14 (Day 0 = stell cell transplant). The initial dose calculated to deliver no more than 100 cGy to critical organs (liver, lung). Doses will be escalated based on cohort of enrollment.
Study NCT00577460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole
Description: Pramipexole ER 0.375 -4.5 mg
Study NCT00577460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets identical to Pramipexole ER tablets
Study NCT03532321 — intervention group
Intervention type: OTHER
Intervention: NA : non interventional study
Description: NA : non interventional study
Study NCT00410956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Study NCT00410956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT01479439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Form: suspension, tablet. Dosage \& frequency: age 6-16 = 0.7mg/kg once daily; age >16 = 50mg once daily. Duration: 6 months
Study NCT00914667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: Single Dose Warfarin 25 mg on Day 1
Study NCT00914667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin plus Fesoterodine
Description: Fesoterodine 8 mg ER tablets QD for 9 Days and Single Dose Warfarin 25 mg on Day 3
Study NCT01427595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days (X2)
Study NCT01427595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estrace
Description: oral estrogen (estrace, 0.5-1 mg once a day for seven days)- X2
Study NCT00653523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe 10 mg once daily
Study NCT00653523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 20 mg daily
Study NCT06309706 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Just observation
Study NCT00999869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Using concentration at 2 units per 0.1 of dilution with normal saline Injection in the first visit and follow up at 1 week, 1,2,3 and 4 months after injection
Study NCT00999869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: Using concentration at 10 mg/ml and equal amount of botulinum toxin A dilution
Study NCT01098721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: WBI-1001
Description: Comparison of two doses (0% and 1.0%) of the the WBI-1001 cream applied topically, twice daily for 12 weeks.
Study NCT01098721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WBI-1001
Description: Comparison of two doses (0% and 1.0%) of the the WBI-1001 cream applied topically, twice daily for 12 weeks.
Study NCT02551445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gradual exposure to food stimuli
Description: Patients with anorexia nervosa will be encouraged to confront their fears and avoidance in relation to food and will be gradually exposed to different food items during the sessions.
Study NCT02010853 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IRMf
Description: evaluation in resting state fMRI during three successive visits:~* During the acute phase within 24 hours~* In 72 hours~* In 3 months
Study NCT02010853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IRMf
Description: evaluation in resting state fMRI during three successive visits:~* During the acute phase within 24 hours~* In 72 hours~* In 3 months
Study NCT01038622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine
Description: 5-day L-arginine treatment
Study NCT01038622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 5-day placebo treatment